United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · IEX Real-Time Price · USD
260.51
-1.89 (-0.72%)
May 6, 2024, 4:00 PM EDT - Market closed

United Therapeutics Revenue

United Therapeutics had revenue of $2.50B in the twelve months ending March 31, 2024, with 26.09% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $677.70M with 33.70% year-over-year growth. In the year 2023, United Therapeutics had annual revenue of $2.33B with 20.20% growth.

Revenue (ttm)
$2.50B
Revenue Growth
+26.09%
P/S Ratio
4.63
Revenue / Employee
$2,138,955
Employees
1,168
Market Cap
11.56B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20232.33B391.20M20.20%
Dec 31, 20221.94B250.80M14.88%
Dec 31, 20211.69B202.20M13.63%
Dec 31, 20201.48B34.50M2.38%
Dec 31, 20191.45B-179.00M-11.00%
Dec 31, 20181.63B-97.50M-5.65%
Dec 31, 20171.73B126.50M7.91%
Dec 31, 20161.60B133.00M9.07%
Dec 31, 20151.47B177.30M13.76%
Dec 31, 20141.29B171.52M15.36%
Dec 31, 20131.12B200.91M21.93%
Dec 31, 2012916.08M172.89M23.26%
Dec 31, 2011743.18M150.28M25.35%
Dec 31, 2010592.90M234.02M65.21%
Dec 31, 2009358.88M77.38M27.49%
Dec 31, 2008281.50M70.55M33.45%
Dec 31, 2007210.94M51.31M32.14%
Dec 31, 2006159.63M43.72M37.71%
Dec 31, 2005115.92M42.33M57.51%
Dec 31, 200473.59M20.25M37.96%
Dec 31, 200353.34M23.22M77.09%
Dec 31, 200230.12M24.39M425.56%
Dec 31, 20015.73M3.68M179.70%
Dec 31, 20002.05M1.61M369.42%
Dec 31, 1999436.50K382.75K712.08%
Dec 31, 199853.75K-62.16K-53.63%
Dec 31, 1997115.91K--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Tenet Healthcare 20.91B
DaVita 12.34B
Solventum 8.20B
Smith & Nephew 5.55B
Charles River Laboratories International 4.13B
Catalent 4.10B
Incyte 3.77B
Exact Sciences 2.50B
Revenue Rankings